Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Moran Wealth Management LLC

Moran Wealth Management LLC boosted its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 23.8% in the first quarter, Holdings Channel.com reports. The firm owned 173,349 shares of the medical equipment provider’s stock after acquiring an additional 33,362 shares during the quarter. Moran Wealth Management LLC’s holdings in Smith & Nephew SNATS were worth $5,509,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Garner Asset Management Corp purchased a new position in Smith & Nephew SNATS during the fourth quarter worth approximately $27,000. Arax Advisory Partners grew its stake in shares of Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Smith & Nephew SNATS during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Smith & Nephew SNATS during the 3rd quarter worth $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth $43,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Smith & Nephew SNATS stock opened at $30.26 on Friday. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79. The firm has a fifty day moving average of $30.30 and a 200-day moving average of $32.51. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.